StockData
C4 Therapeutics, Inc. logo

C4 Therapeutics, Inc. (CCCC) stock

CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/302% below fair value
$2.48−0.05 (-2.17%)

Close on Nov 18, 2026Market cap $304.49MP/E –Yield –

C4 Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

No pe ratio figures for C4 Therapeutics

C4 Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More C4 Therapeutics figures

See a number that looks wrong?